Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

EBS

E

Emergent BioSolutions Inc. (EBS)

NYQ – Real Time Price. Currency in USD

7.93

-0.15 (-1.86%)

At close: Mar 27, 2026, 4:00 PM EDT

8.00

+0.07 (0.88%)

After-hours: Mar 27, 2026, 7:45 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D.

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025.

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company's common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company's common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares.